CA3199945A1 - Pharmaceutical composition for preventing or treating viral perivaginal disease - Google Patents
Pharmaceutical composition for preventing or treating viral perivaginal diseaseInfo
- Publication number
- CA3199945A1 CA3199945A1 CA3199945A CA3199945A CA3199945A1 CA 3199945 A1 CA3199945 A1 CA 3199945A1 CA 3199945 A CA3199945 A CA 3199945A CA 3199945 A CA3199945 A CA 3199945A CA 3199945 A1 CA3199945 A1 CA 3199945A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- vaginal
- compound
- nonionic surfactant
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
- A61K9/025—Suppositories; Bougies; Bases therefor; Ovules characterised by shape or structure, e.g. hollow layered, coated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020-180339 | 2020-10-28 | ||
| JP2020180339 | 2020-10-28 | ||
| PCT/JP2021/006418 WO2022091442A1 (ja) | 2020-10-28 | 2021-02-19 | ウイルス性腟周辺部疾患の予防又は治療のための医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3199945A1 true CA3199945A1 (en) | 2022-05-05 |
Family
ID=81382191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3199945A Pending CA3199945A1 (en) | 2020-10-28 | 2021-02-19 | Pharmaceutical composition for preventing or treating viral perivaginal disease |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230398107A1 (https=) |
| EP (1) | EP4238565B1 (https=) |
| JP (1) | JP7606239B2 (https=) |
| KR (1) | KR20230098175A (https=) |
| CN (1) | CN115734782A (https=) |
| CA (1) | CA3199945A1 (https=) |
| ES (1) | ES3045576T3 (https=) |
| PL (1) | PL4238565T3 (https=) |
| TW (1) | TWI890738B (https=) |
| WO (1) | WO2022091442A1 (https=) |
| ZA (1) | ZA202304812B (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63275519A (ja) * | 1987-05-06 | 1988-11-14 | Taisho Pharmaceut Co Ltd | 難溶性薬物含有顆粒の製造方法 |
| JP2001081031A (ja) | 1999-08-30 | 2001-03-27 | Schering Ag | 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤 |
| JP2007517062A (ja) | 2003-12-29 | 2007-06-28 | アルザ・コーポレーシヨン | 機械的圧縮中に付着抵抗を与える薬物顆粒のコーティング |
| JP5349309B2 (ja) * | 2007-08-03 | 2013-11-20 | 株式会社キノファーマ | 抗ｄｎａウイルス作用を有するアニリン誘導体 |
| JP2010189337A (ja) * | 2009-02-19 | 2010-09-02 | Asahi Breweries Ltd | 難溶性物質を含有する顆粒、錠剤、及び難溶性物質の可溶化方法 |
| JP6138635B2 (ja) * | 2013-08-30 | 2017-05-31 | 旭化成株式会社 | セルロース系核粒子及びその製造方法 |
| WO2020218518A1 (ja) * | 2019-04-25 | 2020-10-29 | 富士製薬工業株式会社 | 医薬製剤およびその製造方法 |
| WO2020218517A1 (ja) * | 2019-04-25 | 2020-10-29 | 富士製薬工業株式会社 | 医薬製剤およびその製造方法 |
-
2021
- 2021-02-19 US US18/033,584 patent/US20230398107A1/en active Pending
- 2021-02-19 KR KR1020237014225A patent/KR20230098175A/ko active Pending
- 2021-02-19 PL PL21885567.4T patent/PL4238565T3/pl unknown
- 2021-02-19 CA CA3199945A patent/CA3199945A1/en active Pending
- 2021-02-19 CN CN202180045812.6A patent/CN115734782A/zh active Pending
- 2021-02-19 WO PCT/JP2021/006418 patent/WO2022091442A1/ja not_active Ceased
- 2021-02-19 JP JP2022558836A patent/JP7606239B2/ja active Active
- 2021-02-19 EP EP21885567.4A patent/EP4238565B1/en active Active
- 2021-02-19 ES ES21885567T patent/ES3045576T3/es active Active
- 2021-02-19 TW TW110105759A patent/TWI890738B/zh active
-
2023
- 2023-04-26 ZA ZA2023/04812A patent/ZA202304812B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022091442A1 (ja) | 2022-05-05 |
| JP7606239B2 (ja) | 2024-12-25 |
| KR20230098175A (ko) | 2023-07-03 |
| EP4238565C0 (en) | 2025-09-24 |
| PL4238565T3 (pl) | 2025-12-22 |
| ES3045576T3 (en) | 2025-11-28 |
| EP4238565A4 (en) | 2024-10-09 |
| EP4238565A1 (en) | 2023-09-06 |
| JPWO2022091442A1 (https=) | 2022-05-05 |
| EP4238565B1 (en) | 2025-09-24 |
| TW202216142A (zh) | 2022-05-01 |
| TWI890738B (zh) | 2025-07-21 |
| US20230398107A1 (en) | 2023-12-14 |
| ZA202304812B (en) | 2024-08-28 |
| CN115734782A (zh) | 2023-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10251884B2 (en) | Treatment of cancer and benign proliferative disorders | |
| EP3424512B1 (en) | Uses of alginic acid sulfate in preparation of drugs and health care products for preventing and treating diseases caused by human papilloma viruses | |
| CN101422585A (zh) | 含有莪术油的药物组合物的制药用途 | |
| EA024609B1 (ru) | Лечение боли, обусловленной дислокацией базального слоя эндометрия | |
| US20240148729A1 (en) | Lopinavir and ritonavir for the treatment of cervix disorders | |
| JP2021525263A (ja) | 処置 | |
| EP4238565B1 (en) | Pharmaceutical composition for preventing or treating viral perivaginal disease | |
| KR20220106777A (ko) | 약제학적 조성물 | |
| CN111686084A (zh) | 一种盐酸小檗碱谷维素片剂在治疗糖尿病中的应用 | |
| CN103599093B (zh) | 一种抗hpv药物制剂及用途 | |
| HK40083240A (en) | Pharmaceutical composition for preventing or treating viral perivaginal disease | |
| RU2318510C1 (ru) | Суппозитории вагинальные на основе 3,3`-дииндолилметана (метиндола) | |
| WO2020088364A1 (zh) | 一种用于抗病毒感染的药物组合物及制备方法 | |
| CN112351779A (zh) | 用于治疗血管肉瘤的口服给药紫杉醇和P-gp抑制剂的治疗组合 | |
| Chituku et al. | The Development of Locoregional Therapies as a Strategy for Reducing Cervical Cancer Mortality in Low to Middle Income Countries. | |
| JP2006069994A (ja) | 発癌抑制用経口投与剤 | |
| CN113769097A (zh) | Egfr/her2抑制剂联合嘧啶类抗代谢药物的用途 | |
| WO2025147598A1 (en) | Device system and use for hpv infection and cervical intraepithelial neoplasia | |
| WO2025160227A1 (en) | Advantageous compounds for treatment of hpv infection and hpv-induced neoplasia | |
| WO2018006689A1 (zh) | 氟维司群在制备治疗无功能垂体腺瘤的药物中的用途 | |
| WO2025147262A1 (en) | Device system and use for hpv infection and cervical intraepithelial neoplasia | |
| Tay et al. | The effects of oral contraceptive steroids, menopause and hormone replacement therapy on the cervical epithelium | |
| CN112022869A (zh) | 野黄芩苷的医药用途 | |
| HK1228291B (en) | Treatment of cancer and benign proliferative disorders | |
| HK1228291A1 (en) | Treatment of cancer and benign proliferative disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250205 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250205 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250210 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250210 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250210 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250305 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250508 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260108 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260209 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260209 |